Abstract | OBJECTIVE: METHODS: One hundred thirty-four patients with ReA who had failed to respond to NSAIDs were recruited from 19 clinics, randomized (double-blind) to receive either SSZ or placebo, and followed up for 36 weeks. The definition of treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. RESULTS: Longitudinal analysis revealed improvement in the patients taking SSZ compared with those taking placebo, which appeared at 4 weeks and continued through the trial (P = 0.02). At the end of treatment, response rates were 62.3% for SSZ treatment compared with 47.7% for placebo treatment. The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. CONCLUSION: SSZ at a dosage of 2,000 mg/day is well tolerated and effective in patients with chronically active ReA.
|
Authors | D O Clegg, D J Reda, M H Weisman, J J Cush, F B Vasey, H R Schumacher Jr, E Budiman-Mak, D J Balestra, W D Blackburn, G W Cannon, R D Inman, F P Alepa, E Mejias, M R Cohen, R Makkena, M L Mahowald, J Higashida, S L Silverman, N Parhami, J Buxbaum, C M Haakenson, R H Ward, B J Manaster, R J Anderson, W G Henderson |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 39
Issue 12
Pg. 2021-7
(Dec 1996)
ISSN: 0004-3591 [Print] United States |
PMID | 8961907
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Anti-Inflammatory Agents
- PHB2 protein, human
- Placebos
- Prohibitins
- Sulfasalazine
|
Topics |
- Adult
- Anti-Inflammatory Agents
(adverse effects, therapeutic use)
- Arthritis, Reactive
(drug therapy)
- Female
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Patient Compliance
- Placebos
(therapeutic use)
- Prohibitins
- Sulfasalazine
(adverse effects, therapeutic use)
- Treatment Outcome
- Treatment Refusal
|